YAP1 and COX2 Coordinately Regulate Urothelial Cancer Stem-like Cells
- 1 January 2018
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 78 (1) , 168-181
Abstract
Overcoming acquired drug resistance remains a core challenge in the clinical management of human cancer, including in urothelial carcinoma of the bladder (UCB). Cancer stem-like cells (CSC) have been implicated in the emergence of drug resistance but mechanisms and intervention points are not completely understood. Here, we report that the proinflammatory COX2/PGE2 pathway and the YAP1 growth-regulatory pathway cooperate to recruit the stem cell factor SOX2 in expanding and sustaining the accumulation of urothelial CSCs. Mechanistically, COX2/PGE2 signaling induced promoter methylation of let-7, resulting in its downregulation and subsequent SOX2 upregulation. YAP1 induced SOX2 expression more directly by binding its enhancer region. In UCB clinical specimens, positive correlations in the expression of SOX2, COX2, and YAP1 were observed, with coexpression of COX2 and YAP1 particularly commonly observed. Additional investigations suggested that activation of the COX2/PGE2 and YAP1 pathways also promoted acquired resistance to EGFR inhibitors in basal-type UCB. In a mouse xenograft model of UCB, dual inhibition of COX2 and YAP1 elicited a long-lasting therapeutic response by limiting CSC expansion after chemotherapy and EGFR inhibition. Our findings provide a preclinical rationale to target these pathways concurrently with systemic chemotherapy as a strategy to improve the clinical management of UCB. Significance: These findings offer a preclinical rationale to target the COX2 and YAP1 pathways concurrently with systemic chemotherapy to improve the clinical management of UCB, based on evidence that these two pathways expand cancer stem-like cell populations that mediate resistance to chemotherapy. Cancer Res; 78(1); 168–81. ©2017 AACR.Keywords
All Related Versions
Funding Information
- Flight Attendant Medical Research Institute Young Clinical Scientist Award (052401 YCSA)
- SPORE (P50 CA098252)
- Allegheny Health Network-Johns Hopkins Cancer Research Fund (80039465)
- Allegheny Health Network-Johns Hopkins Cancer Research Fund (P30CA006973)
- Allegheny Health Network-Johns Hopkins Cancer Research Fund (1R01CA163594-01)
This publication has 45 references indexed in Scilit:
- Normal and neoplastic urothelial stem cells: getting to the root of the problemNature Reviews Urology, 2012
- Targeted silencing of the oncogenic transcription factor SOX2 in breast cancerNucleic Acids Research, 2012
- Prostaglandin E2 promotes intestinal tumor growth via DNA methylationNature Medicine, 2012
- The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiationGenes & Development, 2010
- Arsenic-Specific Stem Cell Selection During Malignant TransformationJNCI: Journal of the National Cancer Institute, 2010
- Eicosanoids and cancerNature Reviews Cancer, 2010
- SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomasNature Genetics, 2009
- Induced Pluripotent Stem Cell Lines Derived from Human Somatic CellsScience, 2007
- The tumor suppressor microRNA let-7 represses the HMGA2 oncogeneGenes & Development, 2007
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionNew England Journal of Medicine, 2005